Introduction
============

COPD is a systemic inflammatory disease characterized by airflow limitation that is not fully reversible.[@b1-copd-11-649] COPD is complicated by a high rate of cardiac diseases[@b2-copd-11-649] and is present in approximately one-third of patients with congestive heart failure (HF).[@b3-copd-11-649],[@b4-copd-11-649] Patients with HF with preserved ejection fraction (pEF) are more likely to have a history of COPD compared with patients with HF with reduced ejection fraction.[@b5-copd-11-649] A proposed paradigm for pEF in patients with HF identifies a systemic proinflammatory state induced by comorbidities, such as COPD, diabetes mellitus (DM), hypertension (HTN), and obesity. This proinflammatory state leads to structural and functional myocardial alterations via increased oxidative stress in the vascular endothelium.[@b6-copd-11-649] Previous studies have examined the relationship between forced expiratory volume and heart disease. Barr et al[@b7-copd-11-649] found that an impaired endothelial function was associated with low forced expiratory volume in 1 second (FEV~1~) and high-resolution computed tomography percentage of emphysema in former smokers early in COPD. In a population-based study, a greater extent of emphysema on computed tomography and more severe airflow obstruction were linearly related to impaired left ventricular (LV) filling, reduced stroke volume, and lower cardiac output without changes in the ejection fraction.[@b8-copd-11-649] Hole et al[@b9-copd-11-649] found a significant inverse relationship between FEV~1~ and death due to ischemic heart disease and stroke. Previous Doppler studies have demonstrated that left ventricular diastolic dysfunction (LVDD) is frequently found in severe patients with COPD.[@b10-copd-11-649],[@b11-copd-11-649] However, these studies had a small sample size, excluded mild-to-moderate COPD, and did not use tissue Doppler echocardiography, which is more accurate than Doppler LV inflow study for detecting LVDD. According to the Heart Failure and Echocardiography Associations of the European Society of Cardiology, diagnostic evidence of diastolic LV dysfunction can be obtained noninvasively by tissue Doppler (*E*/*e*′ ≥15).[@b12-copd-11-649] Thus, here, we evaluated LV diastolic function using tissue Doppler echocardiography in mild-to-moderate patients with COPD.

Our objectives were to evaluate the incidences of LVDD among the COPD and control groups with respiratory failure, determine the relationship between pulmonary function test (PFT) parameters and LVDD (*E*/*e*′), and determine the predictive factor of a high *E*/*e*′ (defined as *E*/*e*′ ≥15) as an index of severe LVDD.[@b12-copd-11-649]

Patients and methods
====================

Study design
------------

Overall, 822 consecutive patients who underwent both PFT and echocardiography simultaneously (within 3 months) for determining the cause of respiratory failure between January 2011 and December 2012 were evaluated ([Figure 1](#f1-copd-11-649){ref-type="fig"}). The age criterion was ≥20 years. The exclusion criteria were presence of acute coronary syndromes (n=28), including acute myocardial infarction, end-stage renal disease requiring dialysis (n=16), past history of acute decompensated HF (n=48), or LV ejection fraction \<50% (n=62). COPD was diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease criteria.[@b13-copd-11-649] Finally, 115 patients with COPD and 115 age- and sex-matched control patients with an LV ejection fraction of ≥50% were enrolled. The control group included patients with interstitial pneumonia (n=69), lung cancer (n=13), tuberculosis (n=9), and other diseases (n=24). The health statuses of patients were obtained using electronic clinical records. This retrospective study was conducted using data from a large university hospital. The protocol used complied with the Declaration of Helsinki and was approved by our institutional ethics committee of Nippon Medical School, which waived the need for patient consent owing to the retrospective nature of the study.

Relevant factors
----------------

The heart rate and systolic blood pressure were simultaneously measured at rest using electrocardiography. Height and weight were measured at the time of PFT, and the body mass index (kg/m^2^) was calculated as an index of obesity. HTN was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of antihypertensive agents. DM was defined as fasting plasma glucose level ≥126.0 mg/dL and 2-hour plasma glucose level \>200 mg/dL during an oral glucose tolerance test or current treatment with antidiabetic agents.[@b14-copd-11-649]

Anemia was defined as hemoglobin level \<13 g/dL in men and \<12 g/dL in women. Chronic kidney disease (CKD) was defined as glomerular filtration rate ≤60 mL/min/1.73 m^2^; this value was estimated using the simplified prediction equation derived from the Modification of Diet in Renal Disease study.[@b15-copd-11-649] Clinical data were obtained from PFTs or echocardiography when the hemodynamic conditions of the patients had stabilized.

Echocardiography parameters
---------------------------

Transthoracic echocardiography was recorded using an iE33 system (Philips Medical Systems, Bothell, WA, USA). We conducted standard, comprehensive, motion-mode (M-mode), two-dimensional echocardiography and Doppler studies according to the American Society of Echocardiog-raphy guidelines.[@b16-copd-11-649] The left auricle diameter, left ventricle end-systolic and end-diastolic diameters, interventricular septal thickness, and posterior wall thickness were measured using M-mode echocardiography from the left parasternal short- and long-axis views. The LV ejection fraction was calculated using the modified Simpson's method. The tri-cuspid regurgitation velocity was obtained by continuous wave Doppler imaging from the right ventricular inflow or the apical four-chamber view position. The transtricuspid pressure gradient (TRPG) was calculated as follows: $$\text{TRPG} = 4 \times \text{tricuspid~regurgitation~velocity}^{2}$$

The peak early diastolic phase (*E*) and late diastolic phase (*A*) mitral inflow velocities and the *E*/*A* ratio were measured using pulsed-wave Doppler echocardiography with the sample volume between the mitral leaflet tips. The mitral annular velocity (*E*′) and mean *E*/*e*′ ratio were measured at the septal and lateral annulus using tissue Doppler imaging.

PFT
---

Pre- and postbronchodilator PFTs were performed using CHSETAC-8900 (Nihon Kohden, Tokyo, Japan), according to the American Thoracic Society (ATS) guidelines.[@b17-copd-11-649] We performed spirometry (forced vital capacity \[FVC\], FEV~1~, and the FEV~1~/FVC ratio) and plethysmography (total lung capacity \[TLC\], residual volume \[RV\], and the RV/TLC ratio). Spirometry quality was assessed according to the ATS/European Respiratory Society recommendations.[@b18-copd-11-649] COPD and COPD severity were defined according to the ATS/European Respiratory Society COPD criteria by using postbronchodilator measures of pulmonary function.[@b19-copd-11-649]

Statistical analyses
--------------------

The SPSS software package Version 20.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analyses. All continuous values and categorical variables are expressed as mean ± standard deviation and the number and percentage of patients, respectively. We compared the control and COPD groups using the unpaired *t*-test. The relationships between PFT parameters and LVDD were tested using Pearson's correlation. Univariate and multivariable logistic regression analyses were performed to identify potential risk factors for a high *E*/*e*′. Age, sex, obesity, anemia, HTN, DM, atrial fibrillation (AF), COPD stage, anemia, and CKD had planned inclusion in the original model. To assess the robustness of the planned model, other potential factors among the baseline characteristics were considered for inclusion in the multivariate model by stepwise selection (significance level for inclusion 0.10). A two-sided probability value of *P*\<.05 was considered statistically significant.

Results
=======

[Table 1](#t1-copd-11-649){ref-type="table"} shows the clinical characteristics of all patients. No significant differences were found between the COPD and control groups in terms of body mass index; prevalence of HTN, DM, AF, or CKD; brain natriuretic peptide levels; hemoglobin levels; LV ejection fraction; or TRPG. However, the COPD group had a significantly higher Brinkman index for smoking compared with the control group. In the COPD group, the COPD severity according to the global initiative was COPD I in 33 (28.7%) patients, II in 42 (36.5%) patients, III in 25 (21.8%) patients, and IV in 15 (13.0%) patients.

Echocardiography and PFT parameters
-----------------------------------

The echocardiography and PFT parameters of the two groups are shown in [Table 2](#t2-copd-11-649){ref-type="table"}. *E*, mean *E*/*e*′ ratio, and the proportion of high *E*/*e*′ as an index of severe LVDD were significantly higher in the COPD group than in the control group. The proportion of high *E*/*e*′ was significantly higher in the severe COPD (Global Initiative for Chronic Obstructive Lung Disease III or IV) group than in the control group. However, no difference was found in the proportion of high *E*/*e*′ between the severe COPD group and mild-to-moderate COPD (Global Initiative for Chronic Obstructive Lung Disease I or II) group (17.5% vs 8.0%, *P*=0.320; [Figure 2](#f2-copd-11-649){ref-type="fig"}). No significant differences were observed between the two groups regarding standard M-mode echocardiography parameters. The COPD group had a significantly lower FEV~1~ and FEV~1~/FVC ratio and a higher RV and RV/TLC ratio compared with the control group. The mean *E*/*e*′ ratio was significantly negatively correlated with FEV~1~ and positively correlated with the RV/TLC ratio of PFT ([Figure 3](#f3-copd-11-649){ref-type="fig"}). However, no significant associations were found between other PFT parameters and the mean *E*/*e*′ ratio ([Table 3](#t3-copd-11-649){ref-type="table"}).

Univariate analysis revealed AF, severe COPD, and anemia to be significant predictive factors for high *E*/*e*′, while multivariate analysis revealed severe COPD and anemia to be significant predictive factors for high *E*/*e*′ ([Table 4](#t4-copd-11-649){ref-type="table"}).

Discussion
==========

This study is a complete, noninvasive hemodynamic investigation of patients with COPD by using echocardiography and PFTs. Our evaluations of mitral inflow and mitral annular velocities confirmed changes in LVDD in patients with COPD compared with the control patients. A significant increase in the *E*/*e*′ ratio was noted in the COPD group. We observed a weak but significant linear association of LVDD as measured by echocardiography, with both postbronchodilator FEV~1~ and the RV/TLC ratio. Univariate and multivariate analyses revealed severe COPD to be a significant predictive factor for high *E*/*e*′. Our data suggest that the cause for LVDD as a complication of COPD includes mechanical exclusion of the heart by pulmonary overinflation.

Many factors contribute to the underlying cause of LVDD in patients with COPD. First, hypoxia and a systemic proinflammatory state lead to atherosclerosis via increased oxidative stress in the vascular endothelium.[@b6-copd-11-649],[@b7-copd-11-649] Second, the severity of hypoxemia and pulmonary artery pressure or pulmonary vascular resistance has been reported to be closely in patients with COPD, indicating a major role in alveolar hypoxia.[@b20-copd-11-649]--[@b23-copd-11-649] Alveolar hypoxia causes constriction of resistance pulmonary arteries, and sustained alveolar hypoxia induces pulmonary vascular remodeling.[@b24-copd-11-649] Pulmonary HTN is observed in half of the patients with severe COPD.[@b25-copd-11-649] Moreover, \~25% of mild-to-moderate patients with COPD without resting pulmonary HTN at onset will develop pulmonary HTN during a 6-year follow-up.[@b26-copd-11-649] Therefore, pulmonary HTN induced by pulmonary vascular remodeling may associate with the LVDD observed in patients with COPD. Third, we demonstrated that the mean *E*/*e*′ ratio as a parameter of LVDD was significantly negatively correlated with FEV~1~ and positively correlated with the RV/TLC ratio of PFT. It may be explained to lead to mechanical exclusion of the heart by pulmonary overinflation. Hyperinflation in very severe patients with COPD can cause increased intrathoracic pressure and decreased venous pressure, with reductions in the blood volumes of both ventricles.[@b27-copd-11-649] Such ventricular interdependence can impair LV filling, causing the LVDD in patients with severe COPD[@b10-copd-11-649],[@b28-copd-11-649] and mild-to-moderate COPD.[@b8-copd-11-649] In this study, we demonstrated that severe COPD was a significant predictive factor for high *E*/*e*′. As a result, hyperinflation may lead to LVDD.

Study limitations
-----------------

The main limitations of this study were the relatively small sample size and the retrospective design. Moreover, the control group included patients with interstitial pneumonia, lung cancer, tuberculosis, and other diseases. Therefore, the control group may need to be limited to a generally healthy cohort in future studies. Previous data suggest that patients with HF with pEF tend to be older with a female predominance.[@b5-copd-11-649],[@b29-copd-11-649] Age is one of the most cited factors affecting LV filling.[@b30-copd-11-649] However, in this study, the control subjects and patients with COPD were age and sex matched. The COPD group had a significantly higher Brinkman index for smoking compared with that of the control group. Smoking itself may cause subclinical changes in the LV function.[@b31-copd-11-649] However, the Brinkman index did not significantly correlate with *E*/*e*′ in our study. Hence, further prospective, large-scale clinical studies are needed.

Conclusion
==========

LVDD as a complication of COPD may be associated with mechanical exclusion of the heart by pulmonary overinflation. Performing PFT for patients with HF, timely diagnosis of COPD and further intervention therapy may lead to pathological improvement and a greater understanding of COPD.
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![Inclusion criteria for the study population.\
**Abbreviation:** LV, left ventricular.](copd-11-649Fig1){#f1-copd-11-649}

![Proportion of high *E*/*e*′ in each group.\
**Notes:** Proportion of high *E*/*e*′ was significantly higher in the severe COPD group (Global Initiative for Chronic Obstructive Lung Disease III or IV) than in the control group (17.5% vs 4.3%, *P*=0.041). However, no difference was found in the proportion of high *E*/*e*′ between the severe COPD group and the mild-to-moderate COPD group (Global Initiative for Chronic Obstructive Lung Disease I or II; 17.5% vs 8.0%, *P*=0.320). *P*-value obtained using unpaired *t*-test.](copd-11-649Fig2){#f2-copd-11-649}

![Correlation between mean *E*/*e*′ and FEV~1~ or RV/TLC ratio in all patients (n=230).\
**Notes:** Mean *E*/*e*′ was significantly associated with FEV~1~ (*r*=−0.263, *P*\<0.001) and RV/TLC ratio (*r*=0.152, *P*=0.036). *P*-value obtained using Pearson's correlation.\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; RV, residual volume; TLC, total lung capacity.](copd-11-649Fig3){#f3-copd-11-649}

###### 

Clinical characteristics of the study population

  Variables                COPD (n=115), mean ± SD   Control (n=115), mean ± SD   *P*-value
  ------------------------ ------------------------- ---------------------------- -----------
  Age (years)              74.4±10.3                 74.4±10.3                    1.000
  Male sex (%)             72.3                      72.3                         1.000
  BMI (kg/m^2^)            21.5±4.3                  22.5±3.8                     0.060
  Hypertension (%)         55.4                      45.5                         0.143
  Diabetes mellitus (%)    20.5                      25.0                         0.428
  AF (%)                   14.3                      8.0                          0.139
  BNP (pg/mL)              118.6±76.5                73.9±109.1                   0.062
  Hemoglobin (g/dL)        12.3±3.1                  12.9±2.0                     0.155
  Creatinine (mg/dL)       1.05±0.93                 0.88±0.34                    0.074
  CKD (%)                  38.4                      41.1                         0.684
  EF (%)                   67.1±9.2                  68.3±8.3                     0.292
  TRPG (mmHg)              32.4±13.0                 34.7±18.9                    0.303
  Smoke (Brinkman index)   1.147.7±869.5             625.3±839.5                  \<0.001

**Notes:** Data presented as mean ± SD unless otherwise indicated. *P*-value obtained using unpaired *t*-test.

**Abbreviations:** BMI, body mass index; AF, atrial fibrillation; BNP, brain-type natriuretic peptide; CKD, chronic heart disease; EF, ejection fraction; SD, standard deviation; TRPG, transtricuspid pressure gradient.

###### 

Echocardiography and pulmonary function test parameters of the study population

  Variables                 COPD (n=115)   Control (n=115)   *P*-value
  ------------------------- -------------- ----------------- -----------
  Echocardiography                                           
   IVST (mm)                9.4±2.2        8.4±1.6           0.183
   PWT (mm)                 9.0±1.7        8.2±1.4           0.354
   LVEDD (mL)               87.8±31.2      92.7±27.6         0.228
   LVESD (mL)               28.4±16.9      27.7±12.3         0.751
   SV (mL)                  59.4±19.1      63.1±21.4         0.181
   LAD (mL)                 35.4±10.3      34.3±8.3          0.398
   *E*/*A*                  0.79±0.41      0.74±0.57         0.396
   *E*                      58.7±18.5      53.3±16.3         0.027
   *e*′ (septal)            5.9±1.7        6.1±5.3           0.779
   *e*′ (lateral)           7.7±2.3        7.8±3.0           0.747
   Mean *E*/*e*′            10.5±5.0       9.1±2.7           0.009
   High *E*/*e*′ (%)        11.3           4.3               0.046
  Pulmonary function test                                    
   FEV~1~(L)                1.33±0.70      1.76±0.73         --
   FVC (L)                  2.46±0.93      2.25±0.99         --
   FEV~1~/FVC ratio (%)     57.8±12.1      79.9±13.1         --
   RV (L)                   2.09±0.68      1.44±0.64         --
   RV/TLC ratio (%)         45.3±10.4      37.5±11.0         --

**Notes:** Data presented as mean ± SD unless otherwise indicated. *P*-value obtained using unpaired *t*-test.

**Abbreviations:** IVST, interventricular septal thickness; PWT, posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; SV, stroke volume; LAD, left atrial dimension; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity.

###### 

The relationship between PFT parameters and mean *E*/*e*′

  Variables                Mean *E*/*e*′   
  ------------------------ --------------- ---------
  PFT                                      
   FEV~1~(L)               −0.263          \<0.001
   FVC (L)                 −0.043          0.526
   FEV~1~/FVC ratio (%)    −0.018          0.791
   RV (L)                  0.112           0.125
   RV/TLC ratio (%)        0.152           0.036
  Smoke (Brinkman index)   −0.089          0.190

**Note:** *P*-value obtained using Pearson's correlation.

**Abbreviations:** PFT, pulmonary function test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity.

###### 

The odds ratio of prediction for high *E*/*e*′

  Variables               Univariate (95% CI)   *P*-value   Multivariate (95% CI)   *P*-value
  ----------------------- --------------------- ----------- ----------------------- -----------
  Age (\>75 years)        2.26 (0.78--6.58)     0.134       2.47 (0.62--6.48)       0.247
  Male sex                0.58 (0.27--2.09)     0.580       --                      --
  Obesity                 1.10 (0.35--3.55)     0.863       --                      --
  Hypertension            1.60 (0.60--4.30)     0.349       --                      --
  Diabetes mellitus       0.94 (0.30--3.00)     0.920       --                      --
  Atrial fibrillation     3.50 (1.13--10.84)    0.030       2.63 (0.75--9.17)       0.130
  COPD (GOLD I or II)     2.87 (0.99--8.35)     0.053       --                      --
  COPD (GOLD III or IV)   5.81 (2.13--15.89)    0.001       6.00 (2.08--17.35)      0.001
  Anemia                  3.39 (1.22--9.40)     0.019       3.34 (1.11--10.08)      0.032
  CKD                     2.03 (0.77--5.36)     0.154       --                      --

**Note:** *P*-value obtained using univariate and multivariable logistic regression analyses.

**Abbreviations:** CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; CKD, chronic kidney disease.
